Spotlight on SERDs for ER+/HER2- Advanced Breast Cancer: What Clinicians Need to Know

Spotlight on SERDs for ER+/HER2- Advanced Breast Cancer: What Clinicians Need to Know

Spotlight on SERDs for ER+/HER2- Advanced Breast Cancer: What Clinicians Need to Know
RestartResume

What role might selective estrogen receptor degraders have in the treatment of ER+/HER2- advanced breast cancer?

  • Overview

    Selective estrogen receptor degraders (SERDs) are a novel class of drugs for the treatment of ER+/HER2- advanced breast cancer. So how exactly do they work to treat this type of advanced breast cancer, and what are the findings from recent trials investigating the clinical utility of SERDs? Get the answers to these and other key questions with Dr. Jennifer Caudle and Dr. Nan Chen, Assistant Professor of Medicine at the University of Chicago School of Medicine.

Facebook Comments

Register

We’re glad to see you’re enjoying Global Women's Health Academy…
but how about a more personalized experience?

Register for free